
SKIN Stock Forecast & Price Target
SKIN Analyst Ratings
Bulls say
Beauty Health Co demonstrated a positive financial performance in 4Q23, reporting revenue of $96.8 million, which exceeded both previous estimates and Street expectations. The company achieved a notable increase in average selling price (ASP) of total systems by approximately 20% quarter-over-quarter, rising to $28.8k, attributed to a higher percentage of direct sales. Additionally, the revenue upside was primarily driven by strong performance in consumables, suggesting a robust demand for the company's innovative aesthetic technologies and products.
Bears say
Beauty Health Co. has demonstrated a concerning trend with its core delivery systems, reporting new placements of 1,210 which reflects a decline of over 30% year-over-year and quarter-over-quarter, significantly below previous estimates. The deceleration in new system placements raises alarms as these systems are critical for driving future consumable sales, which, although exceeding expectations in 4Q23, are vital for achieving profitability targets in 2024. Additionally, management's guidance for 1Q24 shows anticipated sales of $80 million and an adjusted EBITDA loss of $7.5 million, which is notably below prior estimates and suggests a reliance on substantial improvements in the second half of 2024 to meet full-year financial goals.
This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.
SKIN Analyst Forecast & Price Prediction
Start investing in SKIN
Order type
Buy in
Order amount
Est. shares
0 shares